{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:44:35Z","timestamp":1792100675387,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03688-z","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:51:30Z","timestamp":1792097490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Efficacy, and Pharmacokinetics of Agalsidase\u00a0Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase\u00a03, Open-Label, Single-Arm Study"],"prefix":"10.1007","author":[{"given":"Hong","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"3688_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"Y Zurate","year":"2008","unstructured":"Zurate Y, Hopkin R. Fabry\u2019s disease. Lancet. 2008;372:1427\u201335.","journal-title":"Lancet"},{"issue":"2","key":"3688_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"S Garman","year":"2004","unstructured":"Garman S, Garboczi D. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004;337(2):319\u201335. https:\/\/doi.org\/10.1016\/j.jmb.2004.01.035.","journal-title":"J Mol Biol"},{"key":"3688_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","volume":"429","author":"J MacDermot","year":"2001","unstructured":"MacDermot J, MacDermot K. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol. 2001;429:121\u20135.","journal-title":"Eur J Pharmacol"},{"issue":"21","key":"3688_CR4","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp J, Austin H, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139. https:\/\/doi.org\/10.1001\/jama.285.21.2743.","journal-title":"JAMA"},{"key":"3688_CR5","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"J Aerts","year":"2008","unstructured":"Aerts J, Groener J, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3688_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40268-021-00361-4","volume":"21","author":"A Khan","year":"2021","unstructured":"Khan A, Sirrs S, Bichet D, et al. The safety of agalsidase alfa enzyme replacement therapy in Canadian patients with Fabry disease following implementation of a bioreactor process. Drugs R D. 2021;21(4):385\u201397. https:\/\/doi.org\/10.1007\/s40268-021-00361-4.","journal-title":"Drugs R D"},{"key":"3688_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"K MacDermot","year":"2001","unstructured":"MacDermot K, Holmes A, Miners A. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98\u00a0hemizygous males. J Med Genet. 2001;38:750\u201360.","journal-title":"J Med Genet"},{"key":"3688_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2147\/DDDT.S365885","volume":"18","author":"S Feriozzi","year":"2024","unstructured":"Feriozzi S, Chimenti C, Reisin RC. Updated evaluation of agalsidase alfa enzyme replacement therapy for patients with Fabry disease: insights from real-world data. Drug Des Devel Ther. 2024;18:1083\u2013101. https:\/\/doi.org\/10.2147\/DDDT.S365885.","journal-title":"Drug Des Devel Ther"},{"key":"3688_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. https:\/\/doi.org\/10.1186\/s13023-015-0253-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3688_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2022-108523","author":"M Gilchrist","year":"2022","unstructured":"Gilchrist M, Casanova F, Tyrrell J, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2022. https:\/\/doi.org\/10.1136\/jmedgenet-2022-108523.","journal-title":"J Med Genet"},{"issue":"5","key":"3688_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.10754","volume":"7","author":"S Chang","year":"2024","unstructured":"Chang S, Zhan X, Liu Y, et al. Newborn screening for 6 lysosomal storage disorders in China. JAMA Netw Open. 2024;7(5):e2410754. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.10754.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3688_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13023-024-03441-1","volume":"19","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li Y, Li P, Zhang S, Zhiqing Z. Effectiveness and safety of enzyme replacement therapy in the treatment of Fabry disease: a Chinese monocentric real-world study. Orphanet J Rare Dis. 2024;19(1):422. https:\/\/doi.org\/10.1186\/s13023-024-03441-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3688_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s13023-021-02136-1","volume":"16","author":"Q Shen","year":"2021","unstructured":"Shen Q, Liu J, Chen J, et al. Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children\u2019s Hospital in China. Orphanet J Rare Dis. 2021;16(1):509. https:\/\/doi.org\/10.1186\/s13023-021-02136-1.","journal-title":"Orphanet J Rare Dis"},{"key":"3688_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.117851","volume":"556","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Zhang W, Zhao Z, et al. Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients. Clin Chim Acta. 2024;556:117851. https:\/\/doi.org\/10.1016\/j.cca.2024.117851.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"3688_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13023-023-02806-2","volume":"18","author":"Z Lu","year":"2023","unstructured":"Lu Z, Huang G, Yu L, et al. Low skeletal muscle mass as an early sign in children with Fabry disease. Orphanet J Rare Dis. 2023;18(1):199. https:\/\/doi.org\/10.1186\/s13023-023-02806-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3688_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5582\/irdr.2018.01056","volume":"7","author":"J He","year":"2018","unstructured":"He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intractable Rare Dis Res. 2018;7(2):145\u20137. https:\/\/doi.org\/10.5582\/irdr.2018.01056.","journal-title":"Intractable Rare Dis Res"},{"key":"3688_CR17","unstructured":"NMPA Speeds up Pediatric Drug Approvals. Navlin Daily. 2022. https:\/\/www.navlindaily.com\/article\/12163\/nmpa-speeds-up-pediatric-drug-approvals. Accessed Dec 17, 2025."},{"key":"3688_CR18","unstructured":"Takeda Pharmaceuticals International AG. Package insert: agalsidase \u03b1 concentrate for solution for infusion. National Medical Products Administration. 2024."},{"key":"3688_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10\u00a0years\u2019 treatment. Orphanet J Rare Dis. 2015;10:125. https:\/\/doi.org\/10.1186\/s13023-015-0338-2.","journal-title":"Orphanet J Rare Dis"},{"key":"3688_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101122","volume":"40","author":"M Arakawa","year":"2024","unstructured":"Arakawa M, Ikeda Y, Otaka H, Iwashiro S. Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan. Mol Genet Metab Rep. 2024;40:101122. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101122.","journal-title":"Mol Genet Metab Rep"},{"key":"3688_CR21","unstructured":"A Study of REPLAGAL\u00ae in treatment-naive Chinese participants with Fabry disease. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04974749. Accessed Jan 27, 2025."},{"key":"3688_CR22","unstructured":"Summary of product characteristics. Takeda Pharmaceuticals International AG. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf. Accessed Dec 17, 2025."},{"issue":"1","key":"3688_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13023-025-03705-4","volume":"20","author":"JF Gomez-Cerezo","year":"2025","unstructured":"Gomez-Cerezo JF, Fernandez-Martin J, Barba-Romero MA, et al. Current status of the immunogenicity of enzyme replacement therapy in Fabry disease. Orphanet J Rare Dis. 2025;20(1):253. https:\/\/doi.org\/10.1186\/s13023-025-03705-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"17","key":"3688_CR24","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs. 2021;81(17):1969\u201381. https:\/\/doi.org\/10.1007\/s40265-021-01621-y.","journal-title":"Drugs"},{"issue":"1","key":"3688_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","volume":"13","author":"W Mauhin","year":"2018","unstructured":"Mauhin W, Lidove O, Amelin D, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet J Rare Dis. 2018;13(1):127. https:\/\/doi.org\/10.1186\/s13023-018-0877-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3688_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-Stahl E, et al. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17(1):238. https:\/\/doi.org\/10.1186\/s13023-022-02392-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3688_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","volume":"103","author":"DA Hughes","year":"2011","unstructured":"Hughes DA, Barba Romero MA, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2013the Fabry Outcome Survey. Mol Genet Metab. 2011;103(3):207\u201314. https:\/\/doi.org\/10.1016\/j.ymgme.2011.03.022.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"3688_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1023\/b:boli.0000005658.14563.77","volume":"26","author":"F Baehner","year":"2003","unstructured":"Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase\u00a0IIIB study. J Inherit Metab Dis. 2003;26(7):617\u201327. https:\/\/doi.org\/10.1023\/b:boli.0000005658.14563.77.","journal-title":"J Inherit Metab Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03688-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:51:31Z","timestamp":1792097491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03688-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":28,"alternative-id":["3688"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03688-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hong Ren has no competing interests. Jianhua Mao has no competing interests. Rong Wang has no competing interests. Yucheng Chen has no competing interests. Zhengqing Qiu has no competing interests. Jing Peng has no competing interests. Yan Ouyang has no competing interests. Nan Chen has no competing interests. Jiao Ji is an employee of and owns stocks in Takeda APAC Biopharmaceutical Research and Development Co., Ltd. Jaco Botha is an employee of and owns stocks in Takeda Pharmaceuticals International GmbH. Grace Chen is an employee of and owns stocks in Takeda Development Center Americas, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and all relevant documents were approved by the local independent ethics committees (Supplementary Table\u00a0\n                      \n                      ). The Drug Clinical Trial Ethics Committee at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai, China) served as the master ethics committee. This post-approval commitment (PAC) study was performed in accordance with the International Conference on Harmonisation of Good Clinical Practice guidelines, as well as applicable national and local regulatory requirements, and the Declaration of Helsinki, 1964, and its later amendments. Participants provided written informed consent to participate in the study before taking part. For those aged\u2009<\u200918\u00a0years, both participants and their parent(s)\/legally authorized representative gave informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}